| Title: |
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis. |
| Authors: |
Mariottini, Alice1,2 (AUTHOR); Stack, Emily H.1,3 (AUTHOR); Nair, Govind3 (AUTHOR); Nozzoli, Chiara4 (AUTHOR); Wu, Tianxia3 (AUTHOR); Marchi, Leonardo1 (AUTHOR); Boncompagni, Riccardo4 (AUTHOR); Repice, Anna Maria2 (AUTHOR); Fainardi, Enrico5,6 (AUTHOR); Pasquale, Francesca Di7 (AUTHOR); Carlesi, Edoardo6 (AUTHOR); Saccardi, Riccardo1,4 (AUTHOR); Jacobson, Steven1,3 (AUTHOR); Massacesi, Luca1,2 (AUTHOR) massacesi@unifi.it |
| Source: |
Multiple Sclerosis & Related Disorders. Aug2024, Vol. 88, pN.PAG-N.PAG. 1p. |
| Abstract: |
• Predictors of disability after hematopoietic stem cell transplantation (AHSCT) in multiple sclerosis (MS) are lacking. • Cervical spinal cord cross-sectional area (SCCSA) correlates with disability in MS. • SCCSA was investigated in brain MRIs from 11 MS patients treated with AHSCT. • Baseline SCCSA predicted disability change between pre- and one-year post AHSCT. • SCCSA as promising predictive biomarker and screening tool for high-impact procedures. Biomarkers predictive of disability outcomes in individual multiple sclerosis (MS) patients undergoing autologous haematopoietic stem cell transplantation (AHSCT) are currently lacking. As correlations between spinal cord atrophy and clinical disability in MS were previously described, in this study spinal cord size was investigated in MS patients treated with AHSCT, exploring whether baseline spinal cord volume may predict disability progression after AHSCT. relapsing-remitting (RR-) and secondary-progressive (SP-) MS patients treated with AHSCT (BEAM/ATG regimen) at a single academic centre in Florence, who performed at least two standardized brain magnetic resonance imaging (MRIs) scans (acquired between one-year pre-AHSCT to 5 years after AHSCT) were included. Cervical spinal cord atrophy was estimated as upper cervical spinal cord cross-sectional area (SCCSA). Brain volume loss (BVL) was analysed at the same timepoints. Eleven (8 RR-; 3 SP-) MS patients were included. Over a median follow-up of 66 (range 37 - 100) months, no relapses nor brain MRI activity were observed; disability progressed in 2 cases (both SP-MS). Baseline SCCSA was associated with EDSS change between pre- and one-year post-AHSCT. Compared to patients who stabilized, patients who progressed after AHSCT tended to have lower SCCSA at C4 level at baseline and year 1 after AHSCT. Longitudinal changes in SCCSA or BVL did not correlate with EDSS change. Baseline pre-AHSCT SCCSA, but not its longitudinal changes nor BVL, predicted EDSS change within the two years following AHSCT. SCCSA may represent a biomarker of treatment response and a promising screening tool for assessing patient eligibility for high-impact treatments such as AHSCT. [Display omitted] [ABSTRACT FROM AUTHOR] |
| Database: |
Supplemental Index |